Opyl Ltd. (AU:OPL) has released an update.
Opyl Limited has announced that Opin has been successfully rebranded as Trial Screen following its acquisition by Dr. Hugo Stephenson, who plans to invest $1.2 million into the business. Opyl will retain a 20% stake in Trial Screen, allowing it to focus on growing its TrialKey product and improving its financial position to target high-growth areas in clinical trials and medical research.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
